885068-65-5

Basic information

• Product Name: Benzoic acid, 3-[6-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]-, ethyl ester
• CAS NO: 885068-65-5
• Molecular Formula: C22H21Cl2N3O3
• Molecular Weight: 446.333
• Mol File: 885068-65-5.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 3-[6-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 3-[6-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]-, ethyl ester(885068-65-5)
• EPA Substance Registry System: Benzoic acid, 3-[6-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]-, ethyl ester(885068-65-5)

Safety Data

• Hazardous Substances Data: 885068-65-5(Hazardous Substances Data)

Upstream product

• 1016644-41-9 (6-chloro-2-methoxy-pyrimidin-4-yl)-[2-(2,4-dichloro-phenyl)-ethyl]-amine 
• 4334-87-6 [3-(ethoxycarbonyl)phenyl]boronic acid 

Relevant articles and documents

A COMBINATION OF NIACIN AND A PROSTAGLANDIN D2 RECEPTOR ANTAGONIST

The present invention is directed to a pharmaceutical composition comprising Niacin or a pharmaceutically acceptable salt, solvate or N-oxide thereof, or a nicotinic acid receptor agonist, and a compound of formula (I) as defined herein, or an N-oxide thereof, or an ester prodrug thereof, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and its use for treating atherosclerosis, dyslipidemia, diabetes or a related condition while reducing substantial flushing.